Condition (MeSH)
Cerebrospinal Fluid Rhinorrhea
ClinicalTrials.gov lists 11 trials for Cerebrospinal Fluid Rhinorrhea or a narrower condition beneath it. Kuros Biosurgery AG has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Cerebrospinal Fluid Rhinorrhea itself; the rest are tagged with a narrower condition beneath it.
When did Cerebrospinal Fluid Rhinorrhea trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2023 | 3 |
| 2021 | 1 |
| 2018 | 1 |
| 2015 | 2 |
| 2011 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cerebrospinal Fluid Rhinorrhea trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
| Not applicable | 8 |
| Observational | 1 |
How many Cerebrospinal Fluid Rhinorrhea trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 4 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cerebrospinal Fluid Rhinorrhea trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Kuros Biosurgery AG | 1 |
Which drugs are being tested for Cerebrospinal Fluid Rhinorrhea? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Polyglycolic Acid | 1 |
Which publications cover Cerebrospinal Fluid Rhinorrhea? (18)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Risk factors for postoperative CSF leakage after elective craniotomy and the efficacy of fleece-bound tissue sealing against dural suturing alone: a randomized controlled trial. | Journal of neurosurgery | 2014 | Yes |
| Porcine small intestine submucosal graft for endoscopic skull base reconstruction. | International forum of allergy & rhinology | 2013 | Yes |
| Endoscopic endonasal skull base surgery: analysis of complications in the authors' initial 800 patients. | Journal of neurosurgery | 2011 | Yes |
| Negative-pressure and low-pressure hydrocephalus: the role of cerebrospinal fluid leaks resulting from surgical approaches to the cranial base. | Journal of neurosurgery | 2011 | Yes |
| The endoscopic, endonasal, transmaxillary transpterygoid approach to the pterygopalatine fossa, infratemporal fossa, petrous apex, and the Meckel cave. | Journal of neurosurgery | 2010 | Yes |
Showing 5 of 18 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.